Full Name
Lingzhi Wang
Variants
Wang Lingzhi
Wang, L.Z.
Wang, L.-Z.
Wang, L.
 
 
 
Email
phcwl@nus.edu.sg
 
 

Publications

Refined By:
Date Issued:  [2000 TO 2021]
File Format:  Adobe PDF
Type:  Article
Department:  DEAN'S OFFICE (MEDICINE)
Date Issued:  [2010 TO 2019]

Results 1-7 of 7 (Search time: 0.008 seconds).

Issue DateTitleAuthor(s)
12017A novel benzimidazole derivative, MBIC inhibits tumor growth and promotes apoptosis via activation of ROS-dependent JNK signaling pathway in hepatocellular carcinomaDai X.; Wang L. ; Deivasigamni A.; Looi C.Y.; Karthikeyan C.; Trivedi P.; Chinnathambi A.; Alharbi S.A.; Arfuso F.; Dharmarajan A.; Goh B.C. ; Hui K.M. ; Kumar A.P. ; Mustafa M.R.; Sethi G. 
22019A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinomaZhang, M.; Wang, B.; Chong, Q.-Y. ; Pandey, V.; Guo, Z.; Chen, R.-M.; Wang, L. ; Wang, Y.; Ma, L.; Kumar, A.P. ; Zhu, T.; Wu, Z.-S.; Yin, Z.; Basappa; Goh, B.-C. ; Lobie, P.E. 
32018A sensitive liquid chromatography-tandem mass spectrometry method for the determination of nimbolide in mouse serum: Application to a preclinical pharmacokinetics studyWang, L ; Khoa Phan, D.-D; Syn, N; Xiang, X; Song, H; Thuya, W.L ; Yang, S ; Wong, A.L.-A ; Kumar, A.P ; Yong, W.P ; Sethi, G ; Ho, P.C.-L ; Goh, B.C 
42015Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkersLi F. ; Shanmugam M.K. ; Siveen K.S. ; Wang F. ; Ong T.H.; Loo S.Y. ; Swamy M.M.M.; Mandal S.; Kumar A.P. ; Goh B.C. ; Kundu T.; Ahn K.S.; Wang L.Z. ; Hui K.M. ; Sethi G. 
55-Dec-2019MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphomaLi, Boheng ; Yan, Junli ; The, Phyu; Fan, Shuangyi ; Chung, Tae-Hoon; Mustafa, Nurulhuda; Lin, Baohong; Wang, Lingzhi ; Eichhorn, Pieter Johan Adam; Goh, Boon-Cher ; Ng, Siok-Bian ; Kappei, Dennis; Chng, Wee-Joo 
62016Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancerWong A.L.A. ; Sundar R.; Wang T.-T. ; Ng T.-C. ; Zhang B. ; Tan S.-H. ; Soh T.I.P.; Pang A.S.L.; Tan C.-S.; Ow S.G.W.; Wang L. ; Mogro J.; Ho J.; Jeyasekharan A.D. ; Huang Y.; Thng C.-H. ; Chan C.-W. ; Hartman M. ; Iau P.; Buhari S.A. ; Goh B.-C. ; Lee S.-C. 
72019PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoproteinThura M.; Al-Aidaroos A.Q.; Gupta A. ; Chee C.E. ; Lee S.C. ; Hui K.M. ; Li J.; Guan Y.K. ; Yong W.P. ; So J. ; Chng W.J. ; Ng C.H. ; Zhou J. ; Wang L.Z. ; Yuen J.S.P. ; Ho H.S.S. ; Yi S.M.; Chiong E. ; Choo S.P. ; Ngeow J. ; Ng M.C.H. ; Chua C. ; Yeo E.S.A. ; Tan I.B.H. ; Sng J.X.E.; Tan N.Y.Z.; Thiery J.P. ; Goh B.C. ; Zeng Q.